What it is
KPV is the tripeptide lysine-proline-valine, the C-terminal three residues (11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone with both pigmentary and anti-inflammatory activity. Brzoska et al. (2008) reviewed this peptide family and described KPV as an alternative for anti-inflammatory research because it retains the anti-inflammatory activity of alpha-MSH without its pigmentary action. Most published work on KPV comes from gastroenterology laboratories studying mouse models of colitis and cultured intestinal and immune cells.
Mechanism of action
Two mechanistic threads dominate, both from cell and rodent work. The first is transport. Dalmasso et al. (2008) reported that KPV is taken up by PepT1, a di- and tripeptide transporter expressed in intestinal epithelial cells and in immune cells, and characterized that uptake using radiolabeled KPV and competition experiments; in their cell studies nanomolar concentrations of KPV inhibited activation of the NF-κB and MAP kinase inflammatory signaling pathways in human intestinal epithelial lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells. The second is melanocortin signaling. Because KPV is the alpha-MSH tail, melanocortin receptors are an obvious candidate, but Kannengiesser et al. (2008) observed effects in mice carrying a nonfunctional melanocortin-1 receptor, which argues that at least some of the activity does not require that receptor. Neither thread has been tested in people.
What it’s most studied for
Intestinal inflammation is the dominant research question. Investigators have given KPV to mice with chemically induced colitis, using dextran sodium sulfate (DSS) and trinitrobenzene sulfonic acid (TNBS) models and a T cell transfer model, and measured weight recovery, histology and inflammatory cytokines. A second line follows from the first: because chronic colitis raises colon cancer risk in these models, groups have tested KPV in azoxymethane plus DSS colitis-associated cancer models. A third line is delivery, since a tripeptide given by mouth has to survive the gut and reach inflamed tissue; several studies have packaged KPV in nanoparticles and hydrogels for oral targeting. Reviews of the alpha-MSH peptide family also discuss skin and airway inflammation as areas for future work.
Notable findings
Each finding carries the species or population it was observed in and the dose that study used. Doses are reported as research context, exactly as published. They are not guidance.
PepT1 transport and colitis models in mice
Dalmasso et al. (2008) reported that KPV enters intestinal epithelial and immune cells through the peptide transporter PepT1, and that nanomolar concentrations inhibited NF-κB and MAP kinase signaling in cytokine- stimulated human cell lines. Giving KPV orally in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice, with lower expression of pro-inflammatory cytokines. This paper is the origin of the PepT1 framing used in most later KPV work.
- Dose studied
- KPV added to drinking water (mice, DSS and TNBS colitis models); nanomolar concentrations applied to cytokine-stimulated Caco2-BBE, HT29-Cl.19A and Jurkat cells
[2] Dalmasso G et al. · 2008 · PMID 18061177 ↗
Two mouse colitis models and MC1R mutants
Kannengiesser et al. (2008) tested KPV in DSS colitis and CD45RB-high T cell transfer colitis, and in mice expressing a nonfunctional melanocortin-1 receptor. In DSS colitis, KPV-treated mice recovered earlier and regained significantly more body weight, with significantly reduced colonic inflammatory infiltrates and lower myeloperoxidase activity. In the receptor-mutant mice, the authors reported that KPV treatment rescued all treated animals from death during DSS colitis.
- Dose studied
- KPV given to mice with DSS colitis, CD45RB-high transfer colitis or DSS colitis on a nonfunctional melanocortin-1 receptor background; the abstract does not state the amount or route
[3] Kannengiesser K et al. · 2008 · PMID 18092346 ↗
Colitis-associated cancer model in mice
Viennois et al. (2016) induced colitis-associated cancer in mice with azoxymethane followed by DSS, comparing wild-type animals with mice overexpressing human PepT1 and PepT1 knockouts. Tumor number, size and intestinal inflammation were higher in the overexpressing line and lower in the knockouts. KPV reduced tumor development in wild-type mice but had no such effect in PepT1 knockouts, which the authors read as evidence that the effect depends on PepT1 transport.
- Dose studied
- KPV 100 µmol/L given with azoxymethane followed by two rounds of 3% DSS (mice, colitis-associated cancer model)
[4] Viennois E et al. · 2016 · PMID 27458604 ↗
Nanoparticle delivery of oral KPV
Xiao et al. (2017) loaded KPV into hyaluronic acid-functionalized polymeric nanoparticles roughly 272 nm in diameter and gave them by mouth to mice with ulcerative colitis. The authors reported that the nanoparticle formulation accelerated mucosal healing and reduced inflammation, and that encapsulating the particles in a chitosan/alginate hydrogel prevented mucosal damage and lowered TNF-α more than an untargeted nanoparticle hydrogel. The work addresses delivery rather than establishing a clinical effect.
- Dose studied
- Hyaluronic acid-functionalized KPV nanoparticles, with and without a chitosan/alginate hydrogel, given orally (mice, ulcerative colitis model)
[5] Xiao B et al. · 2017 · PMID 28143741 ↗
Study quality
No published human trial of KPV was found, so the evidence is entirely preclinical: mouse models of chemically induced colitis, a T cell transfer colitis model, an azoxymethane plus DSS colon tumor model, and cultured human intestinal epithelial and T cell lines. Much of this work comes from a small number of groups, with the PepT1 line of research concentrated in one laboratory, and several of the studies were designed to test transport or formulation rather than clinical outcomes. Published abstracts often omit the amount and route given to the animals, which limits how precisely the animal work can be described. No controlled human safety data for KPV has been published, and the animal reports reviewed here did not describe treatment-related toxicity. Claims that KPV has been tested in people, for skin or airway conditions, could not be matched to any trial registration or publication.
References
- 1
- 2PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PMID 18061177
- 3Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. PMID 18092346
- 4Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and Molecular Gastroenterology and Hepatology. PMID 27458604
- 5Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. PMID 28143741
- 6July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: votes on nominated bulk drug substances for the 503A list. U.S. Food and Drug Administration.
Free guide
Want more than the summary?
Get our free research guide, or tell us about your practice and we’ll get back to you.